| Market Cap | 276.11M | P/E | - | EPS this Y | 63.20% | Ern Qtrly Grth | - |
| Income | 17.63M | Forward P/E | -3.95 | EPS next Y | -123.80% | 50D Avg Chg | -12.00% |
| Sales | 563k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 21.00% |
| Dividend | N/A | Price/Book | 4.11 | EPS next 5Y | - | 52W High Chg | -32.00% |
| Recommedations | 2.00 | Quick Ratio | 5.87 | Shares Outstanding | 168.50M | 52W Low Chg | 168.00% |
| Insider Own | 1.15% | ROA | -40.23% | Shares Float | 128.44M | Beta | 0.36 |
| Inst Own | 66.33% | ROE | 21.77% | Shares Shorted/Prior | 13.62M/15.37M | Price | 1.74 |
| Gross Margin | 52.40% | Profit Margin | 3,131.79% | Avg. Volume | 3,643,658 | Target Price | 4.05 |
| Oper. Margin | -6,020.78% | Earnings Date | Nov 7 | Volume | 1,671,654 | Change | 0.00% |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
| HC Wainwright & Co. | Buy | Jun 28, 24 |
| Cantor Fitzgerald | Overweight | May 31, 24 |
| HC Wainwright & Co. | Buy | Apr 30, 24 |
| HC Wainwright & Co. | Buy | Mar 22, 24 |
| B. Riley Securities | Neutral | Dec 12, 23 |
| HC Wainwright & Co. | Buy | Aug 11, 23 |
| Stifel | Buy | May 17, 23 |
| HC Wainwright & Co. | Buy | May 5, 23 |
| B. Riley Securities | Buy | Apr 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ragan Paula | President and CEO President and CEO | Nov 01 | Sell | 0.82 | 239,437 | 196,338 | 836,441 | 11/03/23 |
| WYZGA MICHAEL S | Director Director | Aug 18 | Buy | 1.195 | 25,000 | 29,875 | 76,667 | 08/22/23 |
| Stewart Murray | Interim Chief Medica.. Interim Chief Medical Officer | Aug 09 | Sell | 1.06 | 130,056 | 137,859 | 146,504 | 08/11/23 |
| Ragan Paula | President and CEO President and CEO | May 31 | Sell | 1.95 | 6,292 | 12,269 | 557,245 | 05/31/23 |
| Ragan Paula | President and CEO President and CEO | Jun 03 | Sell | 1.21 | 6,292 | 7,613 | 661,806 | 06/06/22 |